Epithelial retinal tears

Retinal epithelial tears may prove to be yet another indication for the use of intravitreal anti-VEGF agents, according to the results of a retrospective casecontrol study. The two-centre study involved nine patients with epithelial retinal tears who received no treatment and 12 patients who received treatment with a mean of 5.75 intravitreal injections of 0.3mg/0.09ml pegaptanib, 1.25mg/0.05ml bevacizumab, or 0.5mg/0.05ml ranibizumab, depending on the time of the intervention and centre where the patients received their therapy. From the third month to the final followup visit, the study’s investigators found a statistically significant difference between the mean visual acuities of the two groups (p = 0.034).

(Coco et al Ophthalmologica 2012; DOI: 10.1159/000338730)